Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1999 2
2006 1
2007 1
2010 1
2011 2
2012 2
2013 1
2014 2
2015 1
2017 1
2018 2
2019 3
2020 3
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Goldhirsch A, et al. Among authors: thurlimann b. Ann Oncol. 2011 Aug;22(8):1736-47. doi: 10.1093/annonc/mdr304. Epub 2011 Jun 27. Ann Oncol. 2011. PMID: 21709140 Free PMC article.
Thus, 'Luminal A' disease generally requires only endocrine therapy, which also forms part of the treatment of the 'Luminal B' subtype. Chemotherapy is considered indicated for most patients with 'Luminal B', 'Human Epidermal growth factor Receptor 2 (HER2) positive …
Thus, 'Luminal A' disease generally requires only endocrine therapy, which also forms part of the treatment of the 'Luminal B' subtyp …
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J, Weder P, Ribi K, Thürlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, Müller A, Membrez-Antonioli V, Gérard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H; Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Huober J, et al. Among authors: thurlimann b. JAMA Oncol. 2023 Oct 1;9(10):1381-1389. doi: 10.1001/jamaoncol.2023.2909. JAMA Oncol. 2023. PMID: 37561451
For group A, 24-month OS was 79.0% (90% CI, 71.4%-85.4%); for group B, 78.1% (90% CI, 70.4%-84.5%). Median PFS with first-line treatment was 8.4 (95% CI, 7.9-12.0) months in group A and 23.3 (95% CI, 18.9-33.1) months in group B. ...Adverse events were less common w …
For group A, 24-month OS was 79.0% (90% CI, 71.4%-85.4%); for group B, 78.1% (90% CI, 70.4%-84.5%). Median PFS with first-line treatm …
Chemotherapy regimens in early breast cancer: major controversies and future outlook.
Joerger M, Thürlimann B. Joerger M, et al. Among authors: thurlimann b. Expert Rev Anticancer Ther. 2013 Feb;13(2):165-78. doi: 10.1586/era.12.172. Expert Rev Anticancer Ther. 2013. PMID: 23406558 Review.
Recommendations favor the use of anthracyclines and taxanes in patients with luminal B disease, while the use of an anthracycline, taxane and alkylating agent is recommended in triple-negative disease. In luminal B disease, the addition of chemotherapy to endocrine …
Recommendations favor the use of anthracyclines and taxanes in patients with luminal B disease, while the use of an anthracycline, ta …
SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients.
Vetter M, Rothgiesser KM, Li Q, Hawle H, Schönfeld W, Ribi K, Riniker S, von Moos R, Trojan A, Kralidis E, Fehr M, Müller A, Thürlimann B; Swiss Group for Clinical Cancer Research (SAKK). Vetter M, et al. Among authors: thurlimann b. Endocr Oncol. 2022 Feb 10;2(1):9-18. doi: 10.1530/EO-21-0009. eCollection 2022 Jan. Endocr Oncol. 2022. PMID: 37435469 Free PMC article.
The primary endpoint was disease control at week 24 (DC24). The null hypothesis was DC24 30% (A) and 15% (B). Thirty-seven patients were recruited (29 in (A) and 8 in (B)); accrual was stopped following an interim analysis demonstrating futility in (A) and slow accr …
The primary endpoint was disease control at week 24 (DC24). The null hypothesis was DC24 30% (A) and 15% (B). Thirty-seven patients w …
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, Chaba K, Imbimbo M, Benedetti F, Kammler R, Hornfeld J, Munzone E, Gianni L, Thurlimann B, Láng I, Pruneri G, Gray KP, Regan MR, Loi S, Colleoni M, Viale G, Kandalaft L, Coukos G, Curigliano G. Rusakiewicz S, et al. Among authors: thurlimann b. Eur J Cancer. 2024 Mar;200:113535. doi: 10.1016/j.ejca.2024.113535. Epub 2024 Jan 24. Eur J Cancer. 2024. PMID: 38309015
Adjuvant bisphosphonates in breast cancer treatment.
Knauer M, Thürlimann B. Knauer M, et al. Among authors: thurlimann b. Breast Care (Basel). 2014 Oct;9(5):319-22. doi: 10.1159/000368760. Breast Care (Basel). 2014. PMID: 25759611 Free PMC article.
Besides postmenopausal patients, several studies including 2 larger studies by the Austrian Breast and Colorectal Cancer Study Group (ABCSG) and the Cancer and Leukemia Group B (CALGB) have shown an increase in bone mineral density in premenopausal women. ...
Besides postmenopausal patients, several studies including 2 larger studies by the Austrian Breast and Colorectal Cancer Study Group (ABCSG) …
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers H, Floris G, Van Limbergen E, Weltens C, Smeets A, Paridaens R, Giobbie-Hurder A, Regan MM, Viale G, Thürlimann B, Vergote I, Christodoulou E, Van Calster B, Neven P. Van Asten K, et al. Among authors: thurlimann b. Oncologist. 2019 Feb;24(2):165-171. doi: 10.1634/theoncologist.2018-0176. Epub 2018 Aug 31. Oncologist. 2019. PMID: 30171067 Free PMC article.
For the interaction with subtype (p = .34), the HR of PR status was 0.79 (95% CI, 0.61-1.01) in luminal A-like and 0.59 (95% CI, 0.46-0.76) in luminal B-like tumors. In luminal A-like tumors, observed 5-year cumulative incidences of distant recurrence were 4.1% for PR-nega …
For the interaction with subtype (p = .34), the HR of PR status was 0.79 (95% CI, 0.61-1.01) in luminal A-like and 0.59 (95% CI, 0.46-0.76) …
Impact of subtypes and comorbidities on breast cancer relapse and survival in population-based studies.
Ess SM, Herrmann C, Bouchardy C, Neyroud I, Rapiti E, Konzelmann I, Bordoni A, Ortelli L, Rohrmann S, Frick H, Mousavi M, Thürlimann B. Ess SM, et al. Among authors: thurlimann b. Breast. 2018 Oct;41:151-158. doi: 10.1016/j.breast.2018.07.011. Epub 2018 Jul 30. Breast. 2018. PMID: 30099326
RESULTS: Luminal A-like subtype represented 46% of all newly diagnosed BC (N = 1831), followed by luminal B-like (N = 1504, 38%), triple negative (N = 436, 11%) and HER2 enriched (N = 204, 5%). ...
RESULTS: Luminal A-like subtype represented 46% of all newly diagnosed BC (N = 1831), followed by luminal B-like (N = 1504, 38%), tri …
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.
Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, von Moos R, Zaman K, Goldhirsch A; Swiss Group for Clinical Cancer Research (SAKK). Pagani O, et al. Among authors: thurlimann b. Ann Oncol. 2017 Feb 1;28(2):305-312. doi: 10.1093/annonc/mdw622. Ann Oncol. 2017. PMID: 27998961 Free article. Clinical Trial.
RESULTS: Combination-TTP was longer than expected in both arms, 12.2 months in Arm A and 10.3 months in Arm B and not significantly different (hazard ratio [HR] 0.7; 95% CI 0.5-1.1; P =0.1). ...Patients without visceral disease had a Combination-TTP of 21.8 months in arm A …
RESULTS: Combination-TTP was longer than expected in both arms, 12.2 months in Arm A and 10.3 months in Arm B and not significantly d …
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
Phillips KA, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Phillips KA, et al. Among authors: thurlimann b. Breast. 2010 Oct;19(5):388-95. doi: 10.1016/j.breast.2010.03.025. Epub 2010 Apr 10. Breast. 2010. PMID: 20385495 Free PMC article. Clinical Trial.
In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed by 3-years letrozole, or (D) 2-years letrozole followed by 3-years tamoxifen. The primary comparison was the difference in composite score …
In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed …
23 results